FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382023148> ?p ?o ?g. }

• W4382023148 endingPage "6110" @default.
• W4382023148 startingPage "6097" @default.
• W4382023148 abstract "(1) Background: recent evidence suggests that long low-dose capecitabine regimens have a synergistic effect with endocrine therapy as aromatase inhibitors (AIs), and might increase overall survival for hormone-receptor-positive, HER2-negative, metastatic breast cancer compared to both treatments. We performed a retrospective study to confirm the efficacy and expand the safety data for capecitabine plus AI (a combination henceforth named XELIA) for this indication. (2) We conducted a single-center retrospective cohort study of 163 hormone receptor-positive metastatic breast cancer patients who received either the XELIA regimen, capecitabine, or an aromatase inhibitor (AI) as single agents in first-line treatment. The primary endpoint was progression-free survival, and the secondary endpoints were overall survival, best objective response, and toxicity incidence. (3) Results: the median progression-free survival for patients receiving XELIA, AI, and capecitabine was 29.37 months (20.91 to 37.84; 95% CI), 20.04 months (7.29 to 32.80; 95% CI) and 10.48 (8.69 to 12.28; 95% CI), respectively. The overall response rate was higher in the XELIA group (29.5%) than in the AI (14.3%) and capecitabine (9.1%) groups. However, the differences in overall survival were not statistically significant. Apart from hand-foot syndrome, there were no statistically significant differences in adverse events between the groups. (4) Conclusions: this retrospective study suggests that progression-free survival and overall response rates improved with the XELIA regimen compared to use of aromatase inhibitors and capecitabine alone. Combined use demonstrated an adequate safety profile and might represent an advantageous treatment in places where CDK 4/6 is not available. Larger studies and randomized clinical trials are required to confirm the effects shown in our study." @default.
• W4382023148 created "2023-06-27" @default.
• W4382023148 creator A5004755903 @default.
• W4382023148 creator A5009496402 @default.
• W4382023148 creator A5011708998 @default.
• W4382023148 creator A5030773329 @default.
• W4382023148 creator A5031392838 @default.
• W4382023148 creator A5035063101 @default.
• W4382023148 creator A5045218411 @default.
• W4382023148 creator A5055015120 @default.
• W4382023148 creator A5058748888 @default.
• W4382023148 creator A5065951801 @default.
• W4382023148 creator A5084768684 @default.
• W4382023148 date "2023-06-24" @default.
• W4382023148 modified "2023-10-18" @default.
• W4382023148 title "Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer" @default.
• W4382023148 cites W1924521789 @default.
• W4382023148 cites W1997935561 @default.
• W4382023148 cites W2018803393 @default.
• W4382023148 cites W2049393913 @default.
• W4382023148 cites W2061401090 @default.
• W4382023148 cites W2086242551 @default.
• W4382023148 cites W2127362596 @default.
• W4382023148 cites W2144915560 @default.
• W4382023148 cites W2163940216 @default.
• W4382023148 cites W2168030291 @default.
• W4382023148 cites W2169965478 @default.
• W4382023148 cites W2187914054 @default.
• W4382023148 cites W2295090382 @default.
• W4382023148 cites W2346624277 @default.
• W4382023148 cites W2401499026 @default.
• W4382023148 cites W2402915576 @default.
• W4382023148 cites W2461857357 @default.
• W4382023148 cites W2521583908 @default.
• W4382023148 cites W2552099557 @default.
• W4382023148 cites W2567825448 @default.
• W4382023148 cites W2723268920 @default.
• W4382023148 cites W2807441606 @default.
• W4382023148 cites W2898318956 @default.
• W4382023148 cites W2910972034 @default.
• W4382023148 cites W2911625234 @default.
• W4382023148 cites W2916358925 @default.
• W4382023148 cites W2978733037 @default.
• W4382023148 cites W2999354318 @default.
• W4382023148 cites W3001574063 @default.
• W4382023148 cites W3005410912 @default.
• W4382023148 cites W3010719773 @default.
• W4382023148 cites W3031922078 @default.
• W4382023148 cites W3034860487 @default.
• W4382023148 cites W3128646645 @default.
• W4382023148 cites W3152831205 @default.
• W4382023148 cites W3157851117 @default.
• W4382023148 cites W3165271511 @default.
• W4382023148 cites W4206140244 @default.
• W4382023148 cites W4206554066 @default.
• W4382023148 cites W4252345112 @default.
• W4382023148 cites W4281869323 @default.
• W4382023148 cites W4291777355 @default.
• W4382023148 doi "https://doi.org/10.3390/curroncol30070454" @default.
• W4382023148 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37504314" @default.
• W4382023148 hasPublicationYear "2023" @default.
• W4382023148 type Work @default.
• W4382023148 citedByCount "0" @default.
• W4382023148 crossrefType "journal-article" @default.
• W4382023148 hasAuthorship W4382023148A5004755903 @default.
• W4382023148 hasAuthorship W4382023148A5009496402 @default.
• W4382023148 hasAuthorship W4382023148A5011708998 @default.
• W4382023148 hasAuthorship W4382023148A5030773329 @default.
• W4382023148 hasAuthorship W4382023148A5031392838 @default.
• W4382023148 hasAuthorship W4382023148A5035063101 @default.
• W4382023148 hasAuthorship W4382023148A5045218411 @default.
• W4382023148 hasAuthorship W4382023148A5055015120 @default.
• W4382023148 hasAuthorship W4382023148A5058748888 @default.
• W4382023148 hasAuthorship W4382023148A5065951801 @default.
• W4382023148 hasAuthorship W4382023148A5084768684 @default.
• W4382023148 hasBestOaLocation W43820231481 @default.
• W4382023148 hasConcept C121608353 @default.
• W4382023148 hasConcept C126322002 @default.
• W4382023148 hasConcept C143998085 @default.
• W4382023148 hasConcept C167135981 @default.
• W4382023148 hasConcept C168563851 @default.
• W4382023148 hasConcept C197934379 @default.
• W4382023148 hasConcept C203092338 @default.
• W4382023148 hasConcept C2775930923 @default.
• W4382023148 hasConcept C2776166826 @default.
• W4382023148 hasConcept C2776694085 @default.
• W4382023148 hasConcept C2777909004 @default.
• W4382023148 hasConcept C2778504769 @default.
• W4382023148 hasConcept C2780739268 @default.
• W4382023148 hasConcept C2781413609 @default.
• W4382023148 hasConcept C526805850 @default.
• W4382023148 hasConcept C530470458 @default.
• W4382023148 hasConcept C71924100 @default.
• W4382023148 hasConceptScore W4382023148C121608353 @default.
• W4382023148 hasConceptScore W4382023148C126322002 @default.
• W4382023148 hasConceptScore W4382023148C143998085 @default.
• W4382023148 hasConceptScore W4382023148C167135981 @default.
• W4382023148 hasConceptScore W4382023148C168563851 @default.

• next